Myron John Tong

Summary

Affiliation: Huntington Medical Research Institutes
Country: USA

Publications

  1. doi request reprint Familial clustering of hepatocellular carcinoma in HBsAg-positive patients in the United States
    Myron John Tong
    Liver Center, Huntington Medical Research Institutes, 660 South Fair Oaks Avenue, Pasadena, CA, 91105, USA
    Hepatol Int 7:1019-29. 2013
  2. doi request reprint Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis
    Myron John Tong
    Liver Center, Huntington Medical Research Institutes, 660 South Fair Oaks Avenue, Pasadena, CA, 91105, USA
    Hepatol Int 9:567-77. 2015
  3. doi request reprint Hepatitis B inactive carriers: clinical course and outcomes
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, Pasadena, California 91105, USA
    J Dig Dis 14:311-7. 2013
  4. ncbi request reprint Treatment of patients with chronic hepatitis B with adefovir dipivoxil
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, Pasadena, California 91105, USA
    Semin Liver Dis 24:37-44. 2004
  5. pmc Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, 660 South Fair Oaks Avenue, Pasadena, California 91105, United States
    World J Gastroenterol 12:6620-6. 2006
  6. pmc Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers
    Myron J Tong
    The Liver Center, Huntington Medical Research Institutes, Pasadena, CA 91105, USA
    Liver Int 27:1356-63. 2007
  7. doi request reprint Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States
    Myron John Tong
    The Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine at the University of California in Los Angeles, CA, USA
    Hepatology 48:1070-8. 2008
  8. doi request reprint Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis
    Myron John Tong
    The Pfleger Liver Institute, Division of Digestive Diseases, David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA, USA
    Dig Dis Sci 54:1337-46. 2009
  9. doi request reprint Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen
    Myron John Tong
    The Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 7:889-93. 2009
  10. doi request reprint Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA
    Myron J Tong
    The Dumont UCLA Liver Cancer Center, Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    J Clin Gastroenterol 44:e63-70. 2010

Detail Information

Publications15

  1. doi request reprint Familial clustering of hepatocellular carcinoma in HBsAg-positive patients in the United States
    Myron John Tong
    Liver Center, Huntington Medical Research Institutes, 660 South Fair Oaks Avenue, Pasadena, CA, 91105, USA
    Hepatol Int 7:1019-29. 2013
    ..The impact of familial clustering of hepatocellular carcinoma (HCC) in hepatitis B virus (HBV)-infected persons in a low HBV endemic area was investigated...
  2. doi request reprint Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis
    Myron John Tong
    Liver Center, Huntington Medical Research Institutes, 660 South Fair Oaks Avenue, Pasadena, CA, 91105, USA
    Hepatol Int 9:567-77. 2015
    ..The progression of HBsAg-positive chronic hepatitis is insidious and unpredictable. Identification of factors leading to either a benign or more serious clinical outcome may assist in decision making for antiviral therapy...
  3. doi request reprint Hepatitis B inactive carriers: clinical course and outcomes
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, Pasadena, California 91105, USA
    J Dig Dis 14:311-7. 2013
    ..We aimed to determine the clinical impact of ALT and HBV DNA elevations during the course of HBV infection...
  4. ncbi request reprint Treatment of patients with chronic hepatitis B with adefovir dipivoxil
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, Pasadena, California 91105, USA
    Semin Liver Dis 24:37-44. 2004
    ..No major drug-related side effects were noted. Adefovir 10 mg/d orally is safe and effective for treatment of chronic hepatitis B...
  5. pmc Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, 660 South Fair Oaks Avenue, Pasadena, California 91105, United States
    World J Gastroenterol 12:6620-6. 2006
    ..To conduct a retrospective study in 400 chronic hepatitis B patients in order to identify hepatitis B viral factors associated with complications of liver disease or development of hepatocellular carcinoma...
  6. pmc Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers
    Myron J Tong
    The Liver Center, Huntington Medical Research Institutes, Pasadena, CA 91105, USA
    Liver Int 27:1356-63. 2007
    ..However, the differences in these viral factors in chronic carriers who seldom develop HCC compared with HCC patients have not been adequately evaluated...
  7. doi request reprint Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States
    Myron John Tong
    The Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine at the University of California in Los Angeles, CA, USA
    Hepatology 48:1070-8. 2008
    ..In addition, if basal core promoter T1762/A1764 mutants and precore A1896 mutants also were included, then 100% of patients who developed HCC would have been identified for treatment...
  8. doi request reprint Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis
    Myron John Tong
    The Pfleger Liver Institute, Division of Digestive Diseases, David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA, USA
    Dig Dis Sci 54:1337-46. 2009
    ..Hepatitis B viral markers and liver tests were used as predictors for development of hepatocellular carcinoma and progression to end-stage liver disease in 128 cirrhosis patients with hepatitis B...
  9. doi request reprint Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen
    Myron John Tong
    The Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 7:889-93. 2009
    ..However, the long-term clinical outcomes of this process are not well established...
  10. doi request reprint Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA
    Myron J Tong
    The Dumont UCLA Liver Cancer Center, Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    J Clin Gastroenterol 44:e63-70. 2010
    ..The aims of this study were to examine the tumor characteristics and liver disease status in HCC patients of Asian ancestry and determine their survival after treatments for HCC...
  11. doi request reprint Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic
    Myron J Tong
    The Liver Center, Huntington Medical Research Institutes, Pasadena, CA 91105, USA
    Dig Dis Sci 55:826-35. 2010
    ..HCC patients often present with poor liver function and large tumors resulting in rapid mortality. The impact of HCC surveillance and subsequent therapy on patient survival remain controversial...
  12. doi request reprint Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update
    Myron John Tong
    Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Gastroenterol Hepatol 26:829-35. 2011
    ..We sought to determine whether these guidelines identified patients who developed hepatocellular carcinoma (HCC) or who died of non-HCC liver-related deaths for antiviral therapy...
  13. doi request reprint The management of chronic hepatitis B in Asian Americans
    Myron J Tong
    Pfleger Liver Institute, Division of Digestive Diseases, University of California School of Medicine, Los Angeles, CA, USA
    Dig Dis Sci 56:3143-62. 2011
    ..These recommendations are based on a review of relevant literature and the opinion of a panel of Asian American physicians with expertise in hepatitis B treatment...
  14. doi request reprint Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience
    Myron John Tong
    Liver Center, Huntington Medical Research Institutes, Pasadena
    J Dig Dis 17:113-21. 2016
    ..This study aimed to compare severe adverse events (SAEs) amongst therapeutic combinations for HCV in a community clinic setting...